Achieve Life Sciences Statistics
Achieve Life Sciences (SP4P) Stock Statistics & Valuation Metrics
Total Valuation
Achieve Life Sciences has a market cap or net worth of EUR 550.53M. The enterprise value is EUR 665.84M.
- Market Cap
- EUR 550.53M
- Enterprise Value
- EUR 665.84M
Share Statistics
Achieve Life Sciences has 102,902,490 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 102,902,490
- Owned by Insiders
- 0.22%
- Owned by Institutions
- 80.18%
Financial Efficiency
Achieve Life Sciences’s return on equity (ROE) is -2.54 and return on invested capital (ROIC) is -150.47%.
- Return on Equity (ROE)
- -2.54
- Return on Assets (ROA)
- -1.31
- Return on Invested Capital (ROIC)
- -150.47%
- Return on Capital Employed (ROCE)
- -1.68
- Revenue Per Employee
- 0
- Profits Per Employee
- -1.95M
- Employee Count
- 28
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Achieve Life Sciences is -4.03. Achieve Life Sciences’s PEG ratio is 0.23.
- PE Ratio
- -4.03
- PS Ratio
- 0.00
- PB Ratio
- 3.24
- Price to FCF
- -12.98
- Price to Operating Cash Flow
- -13.32
- PEG Ratio
- 0.23
Income Statement
In the last 12 months, Achieve Life Sciences had revenue of 0 and earned -54.65M in profits. Earnings per share was -1.25.
- Revenue
- 0
- Gross Profit
- -228.00K
- Operating Income
- -54.88M
- Pretax Income
- -54.65M
- Net Income
- -54.65M
- EBITDA
- -53.60M
- Earnings Per Share (EPS)
- -1.25
Cash Flow
In the last 12 months, operating cash flow was -44.04M and capital expenditures -52,000, giving a free cash flow of -44.09M billion.
- Operating Cash Flow
- -44.04M
- Free Cash Flow
- -44.09M
- Free Cash Flow per Share
- -0.42
Dividends & Yields
Achieve Life Sciences pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -7.71%
- Earnings Yield
- -19.07%
Stock Price Statistics
- Beta
- 1.43
- 52-Week Price Change
- 46.37%
- 50-Day Moving Average
- 6.20
- 200-Day Moving Average
- 4.94
- Relative Strength Index (RSI)
- 37.95
- Average Volume (3m)
- 193
Important Dates
Achieve Life Sciences upcoming earnings date is Mar 11, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 10, 2026
- Next Earnings Date
- Mar 11, 2027
- Ex-Dividend Date
- ―
Financial Position
Achieve Life Sciences as a current ratio of 4.39, with Debt / Equity ratio of 69.50%
- Current Ratio
- 4.39
- Quick Ratio
- 4.39
- Debt to Market Cap
- 0.07
- Net Debt to EBITDA
- 0.11
- Interest Coverage Ratio
- -67.01
Taxes
In the past 12 months, Achieve Life Sciences has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Achieve Life Sciences EV to EBITDA ratio is -4.69, with an EV/FCF ratio of -11.92.
- EV to Sales
- 0.00
- EV to EBITDA
- -4.69
- EV to Free Cash Flow
- -11.92
- EV to Operating Cash Flow
- -11.93
Balance Sheet
Achieve Life Sciences has EUR 201.52M in cash and marketable securities with EUR 13.76M in debt, giving a net cash position of EUR 187.76M billion.
- Cash & Marketable Securities
- EUR 201.52M
- Total Debt
- EUR 13.76M
- Net Cash
- EUR 187.76M
- Net Cash Per Share
- EUR 1.82
- Tangible Book Value Per Share
- EUR 1.70
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Achieve Life Sciences is EUR 12.05, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- EUR 12.05
- Price Target Upside
- 125.27% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 7
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 5.28%
Scores
- Smart Score
- 6
- AI Score
- ―

